CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) announced today that AVONEX® (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, is now available in Japan. AVONEX is available in more than 90 countries, and its introduction in Japan extends Biogen Idec’s leadership in the treatment of MS to an important and underserved market.
